Replies to post #3969 on Halozyme Therapeutics Inc (HALO)

[rod5247]

Halo is way past sell stock as part of deal stage. They sold to Roche around $3 and Baxter around $9. Nothing since then.

Since Halo is planning global Phase III and talking to EMA second half. Look for Halo to enter marketing deal for ex-US and not sell the rights to Peg.

Once Peg is approved for one indication, I think we see many pharma's running trials with Peg.

I don't think Halo has any deals or will enter any deals that limit the value to any potential buyer.